Why combine MET and EGFR inhibitors in Gastric Cancer?

That’s the question that Icarus Consultants’ oncology expert, Sally Church, Ph.D answers on Pharma Strategy Blog.

In an insightful post about “New mechanisms of resistance to MET inhibition,” Sally discusses research by Jeffrey Engelman, Jie Que and colleagues from Mass General recently published in the AACR journal, Cancer Discovery.

Gastric cancer cells have been observed to have an “oncogene addiction” to MET, so impairing or inactivating MET provides a rational for targeted therapies.

However, given that cancer calls can “escape” from an oncogene addiction through mutations or other pathways, combination therapies are often the approach to follow.

Sally proposes on Pharma Strategy Blog that “combining MET and EGFR inhibitors in gastric cancer may be a viable therapeutic strategy.”

, , , , , , , , , , , , , , , , , , ,

error: Content is protected !!